Document is current
Any future updates will be listed below
-
Authors
Mihályová, Jana https://orcid.org/0000-0001-6773-7873
Panovská, Anna https://orcid.org/0000-0003-4955-3039
Šimkovič, Martin https://orcid.org/0000-0003-0331-5334
Smolej, Lukáš https://orcid.org/0000-0002-4187-8595
Špaček, Martin https://orcid.org/0000-0001-5250-8218
Shokralla, Tereza
Kubová, Zuzana
Zuchnická, Jana
Arpáš, Tomáš https://orcid.org/0000-0002-5198-0307
Vodárek, Pavel https://orcid.org/0000-0002-8050-7594
Turcsányi, Peter https://orcid.org/0000-0003-0839-3841
Polcerová, Lenka https://orcid.org/0000-0003-3034-9599
Chrápavá, Marika
Lysák, Daniel https://orcid.org/0000-0001-9391-4247
Brejcha, Martin
Móciková, Heidi https://orcid.org/0000-0003-2034-0769
Doubek, Michael https://orcid.org/0000-0002-1269-6282
-
Funding
Funding for this research was provided by:
University Hospital in Ostrava
- License Information
-
More Information
Article History
Received: 10 August 2025
Accepted: 26 April 2026
First Online: 13 May 2026
Declarations
Ethical approval: The protocol was approved by the independent ethics committees at each site (Ethics Committee of the University Hospital Ostrava; Ethics Committee of the University of Ostrava; Ethics Committee of the University Hospital Brno and Faculty of Medicine, Masaryk University; Ethics Committee of the University Hospital Hradec Králové and Faculty of Medicine in Hradec Králové; Ethics Committee of the General University Hospital in Prague and First Faculty of Medicine; Ethics Committee of the University Hospital Olomouc and Faculty of Medicine and Dentistry; Ethics Committee of the Medical School and Teaching Hospital in Plzeň; Ethics Committee of Hospital Agel, Nový Jičín; Ethics Committee of the University Hospital Královské Vinohrady and Third Faculty of Medicine).
Conflict of interest: Tomáš Arpáš: none; Martin Brejcha: consultancy, conference sponsorship: AbbVie, AstraZeneca, Janssen; Michael Doubek: consultancy, honoraria, conference sponsorship: AbbVie, AstraZeneca, AOP Orphan, Bristol Myers Squibb, Janssen, Novartis; Marika Chrápavá: none; Zuzana Kubová: none; Daniel Lysák: consultancy, honoraria, travel grants: Janssen, AbbVie, AstraZeneca, Novartis; Jana Mihályová: consultancy, honoraria, conference sponsorship: AbbVie, Janssen, Novartis; Heidi Móciková: none; Anna Panovská: honoraria, travel grants: AstraZeneca, Gilead, Janssen, AbbVie; Lenka Polcerová: none; Lukáš Smolej: honoraria, advisory board membership, travel grants: AbbVie, AstraZeneca, Janssen, Roche; Tereza Shokralla: Conference sponsorship: Janssen, Abbvie, Astra Zeneca; Martin Šimkovič: honoraria, advisory board membership, travel grants: AbbVie, AstraZeneca, Janssen; Martin Špaček: consultancy, honoraria, conference sponsorship: AbbVie, AstraZeneca, BeiGene, Johnson&Johnson, Eli Lilly, Swixx Biopharma; Peter Turcsányi: none; Pavel Vodárek: none; Jana Zuchnická: none.
Competing interests: The authors declare no competing interests.
